|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0022885,
umls-concept:C0030705,
umls-concept:C0035668,
umls-concept:C0039593,
umls-concept:C0087111,
umls-concept:C0205556,
umls-concept:C0220847,
umls-concept:C0333052,
umls-concept:C1510438,
umls-concept:C1521871,
umls-concept:C1707455
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-1-8
|
|
pubmed:abstractText |
Hepatitis C virus (HCV)-infected patients were tested for the presence of HCV RNA using two qualitative assays at various time points during interferon-ribavirin therapy. Among patients treated for 48 weeks, transcription-mediated amplification and the COBAS AMPLICOR Hepatitis C Virus Test results at Week 24 predicted subsequent virologic non-response or virologic relapse in 12/15 (80%) and 8/15 (53%) patients, respectively.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0732-8893
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
615-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14711484-Antiviral Agents,
pubmed-meshheading:14711484-Cohort Studies,
pubmed-meshheading:14711484-Female,
pubmed-meshheading:14711484-Follow-Up Studies,
pubmed-meshheading:14711484-Hepacivirus,
pubmed-meshheading:14711484-Hepatitis C,
pubmed-meshheading:14711484-Humans,
pubmed-meshheading:14711484-Interferons,
pubmed-meshheading:14711484-Male,
pubmed-meshheading:14711484-Monitoring, Physiologic,
pubmed-meshheading:14711484-Nucleic Acid Amplification Techniques,
pubmed-meshheading:14711484-RNA, Viral,
pubmed-meshheading:14711484-Retrospective Studies,
pubmed-meshheading:14711484-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:14711484-Ribavirin,
pubmed-meshheading:14711484-Sensitivity and Specificity,
pubmed-meshheading:14711484-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Comparison of the VERSANT HCV RNA qualitative assay (transcription-mediated amplification) and the COBAS AMPLICOR hepatitis C virus test, version 2.0, in patients undergoing interferon-ribavirin therapy.
|
|
pubmed:affiliation |
Division of Clinical Microbiology, Mayo Clinic, Rochester, MN, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
